1 completed, 1 recruiting, 1 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow B-Lymphocytic Leukemia, Chronic: new trials by email Literature Review of B-Lymphocytic Leukemia, Chronic trials Research Report on B-Lymphocytic Leukemia, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine - Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2024-09-03 | 2026-10-16 |
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ibrutinib, Fludarabine, Pembrolizumab - B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2017-09-22 | 2026-01-30 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Chromosome 17 deletion (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, B-Cell (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Neoplasms (2)
fludarabine (2) · Cyclophosphamide (1) · Rituximab (1) · fludarabine phosphate (1) · ibrutinib (1) · pembrolizumab (1)
Asana BioSciences (1) · National Cancer Institute (NCI) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1)
United States (3) · Argentina (1)
Adrian U Wiestner, M.D. (1) · James N Kochenderfer, M.D. (1) · Niranjan Rao, PhD (1)